FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093837118> ?p ?o ?g. }

• W3093837118 endingPage "24" @default.
• W3093837118 startingPage "24" @default.
• W3093837118 abstract "The coronavirus disease 2019 (COVID-19) pandemic is threatening billions of people worldwide. Tocilizumab has shown promising results in retrospective studies in patients with COVID-19 pneumonia with a good safety profile.To evaluate the effect of early tocilizumab administration vs standard therapy in preventing clinical worsening in patients hospitalized with COVID-19 pneumonia.Prospective, open-label, randomized clinical trial that randomized patients hospitalized between March 31 and June 11, 2020, with COVID-19 pneumonia to receive tocilizumab or standard of care in 24 hospitals in Italy. Cases of COVID-19 were confirmed by polymerase chain reaction method with nasopharyngeal swab. Eligibility criteria included COVID-19 pneumonia documented by radiologic imaging, partial pressure of arterial oxygen to fraction of inspired oxygen (Pao2/Fio2) ratio between 200 and 300 mm Hg, and an inflammatory phenotype defined by fever and elevated C-reactive protein.Patients in the experimental arm received intravenous tocilizumab within 8 hours from randomization (8 mg/kg up to a maximum of 800 mg), followed by a second dose after 12 hours. Patients in the control arm received supportive care following the protocols of each clinical center until clinical worsening and then could receive tocilizumab as a rescue therapy.The primary composite outcome was defined as entry into the intensive care unit with invasive mechanical ventilation, death from all causes, or clinical aggravation documented by the finding of a Pao2/Fio2 ratio less than 150 mm Hg, whichever came first.A total of 126 patients were randomized (60 to the tocilizumab group; 66 to the control group). The median (interquartile range) age was 60.0 (53.0-72.0) years, and the majority of patients were male (77 of 126, 61.1%). Three patients withdrew from the study, leaving 123 patients available for the intention-to-treat analyses. Seventeen patients of 60 (28.3%) in the tocilizumab arm and 17 of 63 (27.0%) in the standard care group showed clinical worsening within 14 days since randomization (rate ratio, 1.05; 95% CI, 0.59-1.86). Two patients in the experimental group and 1 in the control group died before 30 days from randomization, and 6 and 5 patients were intubated in the 2 groups, respectively. The trial was prematurely interrupted after an interim analysis for futility.In this randomized clinical trial of hospitalized adult patients with COVID-19 pneumonia and Pao2/Fio2 ratio between 200 and 300 mm Hg who received tocilizumab, no benefit on disease progression was observed compared with standard care. Further blinded, placebo-controlled randomized clinical trials are needed to confirm the results and to evaluate possible applications of tocilizumab in different stages of the disease.ClinicalTrials.gov Identifier: NCT04346355; EudraCT Identifier: 2020-001386-37." @default.
• W3093837118 created "2020-10-29" @default.
• W3093837118 creator A5007530638 @default.
• W3093837118 creator A5008075619 @default.
• W3093837118 creator A5009989443 @default.
• W3093837118 creator A5010296150 @default.
• W3093837118 creator A5011202383 @default.
• W3093837118 creator A5017440327 @default.
• W3093837118 creator A5020137513 @default.
• W3093837118 creator A5022054317 @default.
• W3093837118 creator A5026665975 @default.
• W3093837118 creator A5027943931 @default.
• W3093837118 creator A5028528972 @default.
• W3093837118 creator A5029476886 @default.
• W3093837118 creator A5030276198 @default.
• W3093837118 creator A5030983915 @default.
• W3093837118 creator A5032788350 @default.
• W3093837118 creator A5034220270 @default.
• W3093837118 creator A5037360324 @default.
• W3093837118 creator A5042192227 @default.
• W3093837118 creator A5045916599 @default.
• W3093837118 creator A5046014167 @default.
• W3093837118 creator A5046968872 @default.
• W3093837118 creator A5048088023 @default.
• W3093837118 creator A5052225949 @default.
• W3093837118 creator A5054709938 @default.
• W3093837118 creator A5056814187 @default.
• W3093837118 creator A5060941469 @default.
• W3093837118 creator A5061404336 @default.
• W3093837118 creator A5063120585 @default.
• W3093837118 creator A5064009671 @default.
• W3093837118 creator A5064604203 @default.
• W3093837118 creator A5070244386 @default.
• W3093837118 creator A5073524426 @default.
• W3093837118 creator A5073996478 @default.
• W3093837118 creator A5075691678 @default.
• W3093837118 creator A5076770647 @default.
• W3093837118 creator A5081878436 @default.
• W3093837118 creator A5083942972 @default.
• W3093837118 creator A5089350603 @default.
• W3093837118 date "2021-01-01" @default.
• W3093837118 modified "2023-10-14" @default.
• W3093837118 title "Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia" @default.
• W3093837118 cites W2737436316 @default.
• W3093837118 cites W2796022095 @default.
• W3093837118 cites W2801608146 @default.
• W3093837118 cites W3001118548 @default.
• W3093837118 cites W3008827533 @default.
• W3093837118 cites W3009859788 @default.
• W3093837118 cites W3009885589 @default.
• W3093837118 cites W3014003872 @default.
• W3093837118 cites W3015321334 @default.
• W3093837118 cites W3016263512 @default.
• W3093837118 cites W3021915688 @default.
• W3093837118 cites W3022970339 @default.
• W3093837118 cites W3024237443 @default.
• W3093837118 cites W3036398841 @default.
• W3093837118 cites W4246679501 @default.
• W3093837118 doi "https://doi.org/10.1001/jamainternmed.2020.6615" @default.
• W3093837118 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7577199" @default.
• W3093837118 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33080005" @default.
• W3093837118 hasPublicationYear "2021" @default.
• W3093837118 type Work @default.
• W3093837118 sameAs 3093837118 @default.
• W3093837118 citedByCount "551" @default.
• W3093837118 countsByYear W30938371182020 @default.
• W3093837118 countsByYear W30938371182021 @default.
• W3093837118 countsByYear W30938371182022 @default.
• W3093837118 countsByYear W30938371182023 @default.
• W3093837118 crossrefType "journal-article" @default.
• W3093837118 hasAuthorship W3093837118A5007530638 @default.
• W3093837118 hasAuthorship W3093837118A5008075619 @default.
• W3093837118 hasAuthorship W3093837118A5009989443 @default.
• W3093837118 hasAuthorship W3093837118A5010296150 @default.
• W3093837118 hasAuthorship W3093837118A5011202383 @default.
• W3093837118 hasAuthorship W3093837118A5017440327 @default.
• W3093837118 hasAuthorship W3093837118A5020137513 @default.
• W3093837118 hasAuthorship W3093837118A5022054317 @default.
• W3093837118 hasAuthorship W3093837118A5026665975 @default.
• W3093837118 hasAuthorship W3093837118A5027943931 @default.
• W3093837118 hasAuthorship W3093837118A5028528972 @default.
• W3093837118 hasAuthorship W3093837118A5029476886 @default.
• W3093837118 hasAuthorship W3093837118A5030276198 @default.
• W3093837118 hasAuthorship W3093837118A5030983915 @default.
• W3093837118 hasAuthorship W3093837118A5032788350 @default.
• W3093837118 hasAuthorship W3093837118A5034220270 @default.
• W3093837118 hasAuthorship W3093837118A5037360324 @default.
• W3093837118 hasAuthorship W3093837118A5042192227 @default.
• W3093837118 hasAuthorship W3093837118A5045916599 @default.
• W3093837118 hasAuthorship W3093837118A5046014167 @default.
• W3093837118 hasAuthorship W3093837118A5046968872 @default.
• W3093837118 hasAuthorship W3093837118A5048088023 @default.
• W3093837118 hasAuthorship W3093837118A5052225949 @default.
• W3093837118 hasAuthorship W3093837118A5054709938 @default.
• W3093837118 hasAuthorship W3093837118A5056814187 @default.
• W3093837118 hasAuthorship W3093837118A5060941469 @default.
• W3093837118 hasAuthorship W3093837118A5061404336 @default.
• W3093837118 hasAuthorship W3093837118A5063120585 @default.

• next